Thiazolyl mGluR5 Antagonists for Potency and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective methods to modulate excitatory amino acid receptor-mediated processes and to develop more potent therapeutic agents for treating various diseases related to these receptors, as existing heterocyclic compounds may not offer sufficient potency, selectivity, or pharmacokinetic properties.
Innovation Solution
The development of specific heterocyclic compounds with a 1,3-thiazol-2-yl ring moiety linked by an ethynylene to a pyridyl or pyrimidinyl ring, which are used as antagonists of glutamate receptors, offering improved drug-like properties such as potency, selectivity, and pharmacokinetic properties, and are formulated into pharmaceutically acceptable salts for enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing heterocyclic compounds are used as mGluR5 antagonists, then basic therapeutic function is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying molecular structure parameters - specifically incorporating a 1,3-thiazol-2-yl ring moiety linked by ethynylene to pyridyl or pyrimidinyl rings, and forming pharmaceutically acceptable salts. These structural parameter changes directly improve potency and selectivity while maintaining reasonable molecular complexity
Solution Approach 2:
The patent creates composite molecular structures by combining multiple heterocyclic rings (1,3-thiazole, pyridyl, or pyrimidinyl) connected by ethynylene linkers. This composite approach allows the molecule to achieve superior potency and selectivity profiles that individual heterocyclic structures cannot provide alone
2Adaptability or versatility
If heterocyclic compounds are developed for treating multiple diseases, then versatility is improved, but pharmacokinetic properties may be compromised
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by selecting specific heterocyclic combinations and salt forms that balance solubility, stability, and bioavailability. The 1,3-thiazol-2-yl ethynylene pyridyl/pyrimidinyl structure provides favorable pharmacokinetic properties while maintaining broad therapeutic applicability across multiple disease indications
Data Source
AI summary
The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.